Mecanismo de accin paso a paso Cuando se administra un agonista del receptor de GLP-1 (normalmente mediante inyeccin subcutnea semanal), el frmaco se une a los mismos receptores que la hormona natural produciendo una respuesta amplificada y sostenida: Mayor liberacin de insulina , mejorando el control glucmico sin provocar hipoglucemias
Monitor liver enzymes (ALT, AST), metabolic parameters (HbA1c, lipids), and fibrosis scores (FIB-4) every 36 months
NCT06383390: TRIUMPH-Outcomes: A Phase 3 Study to Investigate the Effect of Retatrutide on MACE and MAKE
Less common but important: pancreatitis, gallbladder issues, low blood sugar (especially if you also take insulin or sulfonylureas)
Mounjaro (active ingredient: tirzepatide) subcutaneous injection Initial FDA Approval: 2022 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
